ProCE Banner Activity

How I Use TRK Inhibitors in Patients With NTRK Fusion–Positive Tumors

Clinical Thought
Read my thoughts on how I approach TRK inhibitor therapy, including testing for NTRK fusions and monitoring for adverse events.

Released: July 10, 2020

Expiration: July 09, 2021

Share

Faculty

Alexander E Drilon

Alexander E Drilon, MD

Chief, Early Drug Development Service
Memorial Sloan Kettering Cancer Center
New York, New York

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Bayer Healthcare Pharma

Genentech TEXT Only

Faculty Disclosure

Primary Author

Alexander E Drilon, MD

Chief, Early Drug Development Service
Memorial Sloan Kettering Cancer Center
New York, New York

Alexander Drilon, MD, has disclosed that he has received consulting fees from AbbVie, AstraZeneca, BeiGene, BergenBio, Blueprint Medicines, Exelixis, Helsinn, Hengrui Therapeutics, Ignyta/Genentech/Roche, Loxo/Bayer/Lilly, MORE Health, Pfizer, Takeda/Ariad/Millennium, TP Therapeutics, Tyra Biosciences, and Verastem; funds for research support from Foundation Medicine; funds for research support paid to his institution from Exelixis, GlaxoSmithKline, Pfizer, PharmaMar, Taiho, and Teva; and royalties from Wolters Kluwer.